Another biotech stock that's approaching a near-term breakout trade is Transcept Pharmaceuticals (TSPT), a specialty pharmaceutical company focused on the development and commercialization of products that address therapeutic needs in the field of neuroscience. This stock is off to a slow start in 2012, with shares off by around 16% so far.
If you look at the chart for Transcept Pharmaceuticals, you'll notice that this stock has been hammered during the last four months, with shares plunging from a high of $12.99 to a recent low of $5.81 a share. During that plunge, shares of TSPT had been consistently making lower highs and lower lows, which is bearish technical price action.
That said, shares of TSPT now look to have bottomed since the stock has found buying interest at around $5.81 to $5.95 during the last two months. That possible bottom has now put a major breakout into focus if TSPT can manage to clear some near-term overhead resistance levels.>>5 Huge Stocks Ready to Slingshot Higher Market players should now look for long-biased trades in TSPT if it can manage to trigger a near-term breakout trade above some overhead resistance levels at $6.70 to $6.73 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 245,600 shares. If we get that action soon, then TSPT could easily re-test and possibly take out some more resistance levels at $7.45 and its 200-day moving average of $7.97 a share. One could buy TSPT off any weakness and simply use a stop close to some near-term support at $6.16 a share. You could also just get long off strength once TSPT clears $6.70 to $6.73 with heavy volume. If you buy off strength, then I would use a stop near its 50-day moving average of $6.51, or even down towards $6.16 if you want to give it more room.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV